Dutch interest group calls for excessive drug-pricing probe

An advocacy group has said it will ask the Netherlands’ competition authority to investigate a drugmaker for setting excessive prices for the only drug that is available on the market for treating a rare genetic disease.


Get unlimited access to all Global Competition Review content